共 1 条
The endocannabinoid 2-arachidonoylglycerol and dual ABHD6/MAGL enzyme inhibitors display neuroprotective and anti-inflammatory actions in the in vivo retinal model of AMPA excitotoxicity
被引:10
|作者:
Kokona, Despina
[1
,7
,8
]
Spyridakos, Dimitris
[1
]
Tzatzarakis, Manolis
[2
]
Papadogkonaki, Sofia
[1
]
Filidou, Eirini
[3
]
Arvanitidis, Konstantinos, I
[3
]
Kolios, George
[3
]
Lamani, Manjunath
[4
,5
,6
]
Makriyannis, Alexandros
[4
,5
,6
]
Malamas, Michael S.
[4
,5
,6
]
Thermos, Kyriaki
[1
]
机构:
[1] Univ Crete, Sch Med, Dept Pharmacol, Iraklion 71003, Crete, Greece
[2] Univ Crete, Sch Med, Dept Toxicol, Iraklion 71003, Crete, Greece
[3] Democritus Univ Thrace, Sch Med, Lab Pharmacol, Alexandroupolis 68100, Greece
[4] Northeastern Univ, Ctr Drug Discovery, Boston, MA 02115 USA
[5] Northeastern Univ, Dept Chem & Chem Biol, Boston, MA 02115 USA
[6] Northeastern Univ, Dept Pharmaceut Sci, Boston, MA 02115 USA
[7] Univ Bern, Bern Univ Hosp, Inselspital, Dept Ophthalmol, CH-3010 Bern, Switzerland
[8] Univ Bern, Bern Univ Hosp, Inselspital, Dept BioMed Res, CH-3010 Bern, Switzerland
关键词:
2-Arachidonoylglycerol;
ABHD6;
MAGL;
CB1/CB2 cannabinoid receptors;
PI3K/Akt;
Retina;
Neuroprotection;
Neuroinflammation;
Microglia;
D O I:
10.1016/j.neuropharm.2021.108450
中图分类号:
Q189 [神经科学];
学科分类号:
071006 ;
摘要:
The endocannabinoid system has been shown to be a putative therapeutic target for retinal disease. Here, we aimed to investigate the ability of the endocannabinoid 2-arachidonoylglycerol (2-AG) and novel inhibitors of its metabolic enzymes, alpha/beta-hydrolase domain-containing 6 (ABHD6) and monoacylglycerol lipase (MAGL), a) to protect the retina against excitotoxicity and b) the mechanisms involved in the neuroprotection. Sprague-Dawley rats, wild type and Akt2(-/-) C57BL/6 mice were intravitreally administered with phosphate-buffered saline or (RS)-alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid hydrobromide (AMPA). 2-AG was intravitreally co-administered with AMPA in the absence and presence of AM251 or AM630 (cannabinoid 1 and 2 receptor antagonists, respectively) or Wortmannin [Phosphoinositide 3-Kinase (PI3K)/Akt inhibitor]. Inhibitors of ABHD6 and dual ABHD6/MAGL (AM12100 and AM11920, respectively) were co-administered with AMPA intravitreally in rats. Immunohistochemistry was performed using antibodies raised against retinal neuronal markers (bNOS), microglia (Iba1) and macroglia (GFAP). TUNEL assay and real-time PCR were also employed. The CB2 receptor was expressed in rat retina (approx. 62% of CB1 expression). 2-AG attenuated the AMPA-induced increase in TUNEL+ cells. 2-AG activation of both CB1 and CB2 receptors and the PI3K/Akt downstream signaling pathway, as substantiated by the use of Akt2(-/-) mice, afforded neuroprotection against AMPA excitotoxicity. AM12100 and AM11920 attenuated the AMPA-induced glia activation and produced a dose-dependent partial neuroprotection, with the dual inhibitor AM11920 being more efficacious. These results show that 2-AG has the pharmacological profile of a putative therapeutic for retinal diseases characterized by neurodegeneration and neuroinflammation, when administered exogenously or by the inhibition of its metabolic enzymes.
引用
收藏
页数:15
相关论文